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This report presents a case of primary anorectal melanoma. A 63-year–old male presented with blood in stool.
Rectal digital examination and proctoscopy revealed a mass in the anorectal junction. Transanal polypectomy was
performed. Histopathology and immunohistochemistry with Melan A showed a malignant anorectal melanoma
with positive resection margins. Abdomino-perineal rectum resection was performed after excluding distant metastasis.
Four month later, the patient was readmitted with metastases to the liver and to the gastric mucosa. Best supportive
care was initiated. This case report demonstrates the aggressive nature of this rare tumor and appeals for a less
aggressive management while maintaining the quality of life.
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Primary anorectal malignant melanoma is an extremely
rare malignancy that is thought to arise from melano-
cytes in the mucosa around the anorectal junction.
AMM is associated with a relatively poor prognosis, and
surgical resection is the only curative treatment option.
This case demonstrates the aggressive nature of this rare
entity.
Case presentation
A 63-year-old man presented with a history of blood in
the stool. Rectal examination revealed a mass in the
lower rectum. A broad-based rectal polyp about 6 cm
from the anal verge was seen on proctoscopy, and biop-
sies were taken (Figure 1). Histopathology showed a
hyperplastic polyp. A transanal polypectomy was per-
formed after colonoscopy. Histopathology diagnosed a
malignant melanoma (Figure 2) with positive stains for
melan A on immunohistochemistry (Figure 3), with
positive resection margins (pT4bR1). Other primary sites
and distant metastases were excluded. The patient
was managed with abdominoperineal resection (APR),* Correspondence: peter.ambe@helios-kliniken.de
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board. Surgery and recovery were uneventful. The final
tumor stage was pT4bN0 (0/15) cM0pR0, stage IIC
(UICC). Four months later, the patient was readmitted
with tenderness in the right upper quadrant. Ultrasound
demonstrated multiple metastatic lesions in the liver
(Figure 4). Endoscopy revealed pigmented lesions in the
gastric mucosa (Figure 5); Histopathology confirmed
metastasis of a malignant melanoma. Best supportive
care was initiated.Discussion
First reported by Moore DW in 1857 [1], AMM is an ex-
tremely rare malignancy that is thought to arise from
melanocytes in the mucosa around the anorectal junc-
tion. AMM constitutes about 0.05% of all anorectal
malignancies [2,3]. The rare nature of this entity is
represented by the limited number of cases described in
the medical literature. The largest series from a single cen-
ter included 85 cases from the Memorial Sloan-Kettering
Cancer Center, reported by Brady et al. in 1995 [3].
AMM is mostly seen in the sixth decade, with a female
predominance [4,5], and rectal bleeding is the most
common symptom. Changes in bowel movements, rectal
pain, and inguinal mass may also be present. Hemor-
rhoids, polyps, and other malignancies are the most
common differential diagnoses [3,4].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Figure 1 Endoscopic finding. Proctoscopy revealed a mass at the
anorectal junction.
Figure 3 Immunohistochemistry. Immunohistochemical staining
with Melan A confirmed the presence of melanocytes in the
malignant cells.
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ation. Proctoscopy usually reveals a hemorrhoid-like pig-
mented lesion near the anorectal junction, on which a
biopsy must be performed. The histopathologic findings
are similar to those of melanomas of other origins (that
is. the identification of melanin and immunohistochemi-
cal staining for S100, HMD-45, and/or Melan A [6].
After the histologic diagnosis of AMM, a complete
staging and search for possible distant metastases
(colonoscopy, computed tomography of the abdomen and
thorax, MRI of the pelvis and brain), as well as ruling out
primary sites (skin and retina), are mandatory.Figure 2 Hematoxylin and eosin stain. Infiltration of the mucosa
through malignant cells.Each patient with AMM should be discussed in an
interdisciplinary board, and treatment should be individ-
ualized based on the tumor size, age, comorbidities, and
absence or presence of metastases.
Surgical resection is the mainstay of treatment [5,7-9].
APR with or without bilateral inguinal lymphadenec-
tomy and wide local excision (WLE) have been used
to manage patients with AMM. APR is thought to re-
duce the probability of recurrence by controlling the
spread to mesenteric lymph nodes and creating a larger
negative resection margin [3,4,9,10]. However, avail-
able data suggest no significant difference in survival
among patients managed with APR and WLE. Be-
cause APR is associated with high rates of morbidity
and colostomy-associated decrease in the quality of
life, many authors advocate WLE if negative marginsFigure 4 Liver ultrasound. Multiple liver lesions.
Figure 5 Upper GI endoscopy. Pigmented lesion in the gastric
mucosa stained positive for Melan A.
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have no benefit [11].
The prognosis is poor, with overall survival rate <20%
in 5 years. Age >60 years and lesions >1 cm in diameter
have been identified as prognostic factors [3,4,8,9].
Conclusion
In the case presented, AMM was diagnosed after transa-
nal polypectomy with positive margins; thus APR was
performed. Despite aggressive surgical management, dis-
ease progression was very rapid; with the development
of hepatic and gastric metastases within 4 months. This
case demonstrates the aggressive nature of AMM and
questions the role of aggressive surgery (for example,
APR) in the management of AMM. Therefore, until
more evidence becomes available, the quality of life must
be kept in focus when managing AMM, as is the case
with WLE.
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